# Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

> **NCT00010049** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 105 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00010049
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02-27
- **Primary completion:** 2005-03-17
- **Final completion:** 2006-08-15
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2018-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00010049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00010049, "Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00010049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*